Savior Lifetec Corporation (TPEX:4167)

Market Cap	5.82B +13.2%
Revenue (ttm)	1.20B -1.3%
Net Income	537.45M +194.7%
EPS	1.71 +200.0%
Shares Out	310.44M
PE Ratio	10.96
Forward PE	n/a
Dividend	0.81 (4.29%)
Ex-Dividend Date	Jul 14, 2025

Volume	1,215,842
Average Volume	920,548
Open	18.55
Previous Close	18.75
Day's Range	18.55 - 18.95
52-Week Range	16.45 - 22.60
Beta	0.08
RSI	33.87
Earnings Date	May 14, 2026

About Savior Lifetec

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Tainan City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 384
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4167

Financial Performance

In 2025, Savior Lifetec's revenue was 1.20 billion, a decrease of -1.28% compared to the previous year's 1.22 billion. Earnings were 537.45 million, an increase of 194.69%.